Cara Therapeutics Inc

NASDAQ:CARA  
15.22
+0.29 (+1.94%)
Products

Vifor Pharma And Cara Therapeutics Announce FDA Approval Of Korsuva Injection For Treatment Of Pruritus In Hemodialysis Patients

Published: 08/24/2021 05:13 GMT
Cara Therapeutics Inc (CARA) - Vifor Pharma and Cara Therapeutics Announce U.S. FDA Approval of Korsuva™ Injection for the Treatment of Moderate-to-severe Pruritus in Hemodialysis Patients.
Promotional Launch of Korsuva™ Injection in U.S. is Expected in Q1 2022, With Reimbursement in H1 2022.